349 results about "Mother cells" patented technology

The present disclosure provides a recombinant yeast cell for making ethanol. The recombinant yeast cell comprises a first genetic modification to increase an ethanol yield in the recombinant yeast cell when compared to a parental yeast cell. The recombinant yeast cell also comprises a second genetic modification capable of increasing pyruvate decarboxylase activity in the recombinant yeast cell when compared to the parental yeast cell. The parental yeast cell lacks the first genetic modification and the second genetic modification. The present disclosure also provides methods for making the recombinant yeast cell as well processes for using the recombinant yeast cell to make ethanol.

The invention relates to an application of a regulator in improving the maturation quality of frozen pig oocytes, the regulator is N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyryl, and the regulator improves the maturation quality of the frozen pig oocytes by improving the mitochondrial function of the frozen pig oocytes after in-vitro maturation. The invention provides a new application of N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyramide, namely the N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyramide is used for developing a novel oocyte vitrification freezing solution and an in-vitro maturation culture solution, and the obtained high-quality oocytes can be beneficial to embryo biotechnology researches such as in-vitro fertilization and somatic cell nuclear transplantation.

Preparation for an siRNA and drug co-delivery system for efficiently targeting glioma initiating cells, and a use; D VAP targeting peptide modification is performed on exosomes by utilizing a click chemistry method, siRNA and mitoxantrone are loaded into the exosomes, and construction is performed to obtain a target-modified drug carrier exosome DVAP-Exo / siRNA / MIT. The target-modified exosome co-carries chemotherapeutic mitoxantrone, which has a strong killing effect on glioma initiating cells and can trigger immunogenic cell death, and a small interfering nucleic acid (siNotch 1), which is capable of reducing glioma initiating cell stemness; targeted tracking and killing of residual glioma initiating cells and tumor cells are achieved, and a new avenue is provided for glioblastoma treatment.

A method for domesticating CHO-K1 cells into high-expression cells, comprising the following steps: culturing adherent CHO-K1 cells in a complete culture medium, to obtain log growth CHO-K1 cells; transferring the log growth CHO-K1 cells to a serum-free medium for suspension culture; performing a first liquid replacement domestication, to obtain domesticated CHO-K1 cells; placing the domesticated CHO-K1 cells in a chemically defined medium for suspension culture; performing a second liquid replacement domestication, to obtain domesticated suspended CHO-K1 cells; performing monoclonalization on the domesticated suspended CHO-K1 cells, to obtain CHO-K1 monoclonal cells; and screening the CHO-K1 monoclonal cells, to obtain high-expression CHO-K1 monoclonal cells. This method can domesticate CHO-K1 original parent cells into suspended cells, and screen cells having higher expression capability from the domesticated cell population, thereby improving expression levels.

The invention discloses a double-target chimeric antigen receptor for co-expression of CD47 and IL-15, a CAR-T cell and application of the CAR-T cell, and belongs to the technical field of genetic engineering, the double-target chimeric antigen receptor comprises a single-chain antibody scFv-EGFRv III, a single-chain antibody scFv-VEGF, CD47 and IL-15; the nucleotide artificial sequence of the single-chain antibody scFv-EGFRv III is as shown in SEQ ID NO. 6; the nucleotide artificial sequence of the single-chain antibody scFv-VEGF is as shown in SEQ ID NO. 9. According to the application disclosed by the invention, by performing sequence optimization on targets EGFRvIII and VEGF, the anti-tumor effect of CAR-T cells in glioblastoma can be improved, and by integrating immune checkpoint molecules CD47 and interleukin-15, the immunosuppression function of a CD47-SIRP alpha signal channel can be locally exerted.

The present invention relates to a Synthetic Cellular Advanced Signal Adapter (SCASA) system and method comprising a genetically modified yeast cell capable of modulating a receiver cell, preferably a human immune cell. The invention provides systems to dynamically modulate the phenotype of the receiver cell in response to dynamic stimulation of the genetically modified yeast cell.

The invention discloses an application of a Smad6 gene in promoting reprogramming of fibroblasts into stem cells. According to the application, Smad2 / 3 activation is inhibited through overexpression of the Smad6 gene, and up-regulation of important transcription factors C-Myc, Nanog and Oct4 in the stem cell state is promoted to be maintained and regulated, so that fibroblasts are promoted to be reprogrammed into the stem cells. According to the method, the roe mother cell extracting solution is adopted as an inducer to induce fibroblasts to be reprogrammed into the stem cells, and the materials are low in cost, wide in source and safe. According to the application disclosed by the invention, by means of overexpression of the Smad6 gene, fibroblasts induced by a fish egg mother cell extracting solution are promoted to be reprogrammed into stem cells, expression of stem cell related genes C-Myc, Nanog and Oct4 is promoted, activation of a TGF-beta signal channel is inhibited, expression of TGF-beta signal channel related genes Smad2, Smad3 and Smad4 is regulated and controlled, and the stem cells are obtained. The efficiency of reprogramming the somatic cells into the stem cells is improved, and the application of reprogramming is greatly promoted.

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

The invention belongs to the field of immune cell therapy, and particularly relates to application of a double-target CAR-T cell to treatment of systemic lupus erythematosus and other B-cell autoimmune diseases. A first target point of the chimeric antigen receptor is CD19, a second target point of the chimeric antigen receptor is BCMA, and the chimeric antigen receptor with the Loop structure is specifically the chimeric antigen receptor with the Loop structure, and the structure of the chimeric antigen receptor with the Loop structure is shown as follows: L-VL, CD19-VH, BCMA-VL, BCMA-VH and CD19-H-TM-C-CD3zeta; the BCMA-CD19 CAR-T cell transduced by the chimeric antigen receptor can more comprehensively block the way of generating the autoantibody in the process of targeting CD19 and BCMA, and can more completely cover B cells, plasma mother cells and plasma cells which generate the autoantibody and are in a plurality of differentiation stages; therefore, the double-target CAR-T therapy designed on the basis of the concept can be used for treating refractory SLE, and is expected to obtain quicker relieving and deeper and lasting curative effects.

The invention discloses a method for optimizing the maturation effect of cattle and sheep oocytes through CNP pretreatment, and relates to the technical field of biological breeding, the method comprises the following steps: S1, selecting and treating donor cells; s2, collection of oocytes; s3, in-vitro maturation culture of the oocytes: after the pre-maturation treatment, transferring the oocytes into a maturation culture solution for continuous culture under the in-vitro culture condition of air containing 5% CO2, keeping the culture temperature of the oocytes within 1-20 hours at 38.5-39 DEG C, and keeping the culture temperature of the oocytes within 20-28 hours at 39-39.5 DEG C; s4, culturing and screening reconstructed embryos; s5, preparing and transplanting a receptor animal; and S6, performing subsequent monitoring and management. According to the method, the culture temperature is kept at 38.5-39 DEG C within 1-20 hours, the culture temperature is kept at 39-39.5 DEG C within 20-28 hours, a series of enzymes and signal channels in the oocytes can be effectively activated by accurately controlling the culture temperature, and the survival rate and the development quality of the oocytes are improved.

The invention relates to the fields of molecular biology and genetic engineering, and relates to a cherax quadricarinatus egg cell guide peptide, a fusion protein, a nucleic acid molecule, a recombinant expression vector, a host cell, a method for guiding a foreign protein to enter a cherax quadricarinatus egg cell and application of the cherax quadricarinatus egg cell guide peptide. The amino acid sequence of the cambarus clarkii egg cell guide peptide is as shown in SEQ ID NO. 1. According to the invention, green fluorescent protein (eGFP) is used as example protein, which proves that the polypeptide can successfully deliver foreign protein. The breakthrough can lay a technical foundation for introducing a gene editing tool (such as a CRISPR-Cas9 system) into a crayfish oocyte, and is expected to be widely applied to the fields of crayfish breeding, functional gene research, aquaculture gene improvement and the like.

The invention belongs to the technical field of biological medicines, and particularly discloses an inflammatory memory activated epidermal stem cell bionic vesicle as well as a preparation method and application thereof. The epidermal stem cell bionic vesicle is obtained by adding lipopolysaccharide into a serum-free culture medium to induce and culture epidermal stem cells, continuously extruding a cell suspension through an extruder of a micron-sized polycarbonate film, and carrying out centrifugal separation. The LEM preparation method provided by the invention is simple, efficient and good in biocompatibility, not only retains the repair characteristic of mother cells, but also can induce neutrophil to transform to N2 phenotype, and has a better inflammation regulation effect, so that wound healing and tissue repair are promoted, and the LEM has a better application prospect and a better application value.

A yeast cell for use in the treatment and / or alleviation of allergy and / or symptoms caused by allergy, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown from a yeast cell treated with electromagnetic waves in the range of 1 GHz to 300 GHz, and composition comprising such a yeast cell.

The present invention addresses the problem of providing: a method for preparing hepatic lineage cells in a large amount and with high purity; and a method for preparing liver system cells which can achieve high graft survival rate in a living body.　The present invention provides: a hepatoblast proliferation promoter and a culture medium, each of which contains a ROCK inhibitor, a TGFβ signaling pathway inhibitor, a Wnt signaling pathway activator, and a growth factor; and a proliferation / culture method using the hepatoblast proliferation promoter or the culture medium.

Disclosed herein are genetically engineered yeast cells capable of producing xylitol. The engineered yeast cell may comprise an exogenous polynucleotide sequence encoding a sugar phosphatase enzyme comprising a sequence at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to at least one of SEQ ID NOs: 8 and 20.

A method of analysing a sample of a plurality of fish oocytes (100) is disclosed The method comprises, for each oocyte in the sample: capturing a first set of images of the oocyte from a plurality of rotational angels when rotated about a first axis of rotation; capturing a second set of images of the oocyte from a plurality of rotational angels when rotated about a second axis of rotation, which second axis of rotation is orthogonal to the first axis of rotation; identifying at least one characteristic (104) of lipid droplet coalescence in the captured first and second sets of images; and based on the identified at least one characteristic of lipid droplet coalescence, classifying the oocyte as belonging to one of a plurality of predefined categories, and based on the distribution of the sampled oocytes in the plurality of categories, attributing a quality parameter to the sample of oocytes, the quality parameter being any one of: a predicted fertilisation rate of the sampled oocytes; a predicted eyed-embryo success rate of the sampled oocytes; and a predicted hatching success rate of the sampled oocytes. A computer-implemented method of attributing a quality measure to a sample of fish oocytes is also disclosed, as is a related computer program and a related oocyte analysis apparatus. A computer-implemented method for training a neural network for use in a system for analysing a sample of fish oocytes is also disclosed.

The invention relates to a method for electrically activating oocytes based on nanosecond pulses. Single oocytes are sequentially and uniformly arranged between two parallel electrodes of an electrode dish, the electrode dish is characterized in that the distance between the electrodes is 1 mm, the electrodes are placed in a culture dish, and the two ends of the two electrodes are sealed; a culture solution is firstly put between the electrodes which are arranged in parallel, mineral oil is covered to prevent the culture solution from being evaporated, after preheating treatment, oocytes are sequentially and uniformly put between the two electrodes which are arranged in parallel one by one, and then nanosecond pulse electric activation treatment is applied. The electrodes which are arranged in parallel are adopted, the oocytes are sequentially and uniformly placed between the electrodes in a single mode, the situation that the electric pulse effect is reduced due to adhesion and stacking of all the cells is avoided, the oocytes receive uniform and equivalent electric pulse sequences, the action effect and stability of electric pulses on the cells are obviously improved, and the operation efficiency of the oocytes is improved. And the reliability and reproducibility of a test conclusion are improved.

The invention relates to an astroblastoma (ABM) cell model as well as a construction method and application thereof. The astroblastoma cell model is a human induced neural progenitor cell which carries and can express MN1: BEND2 and / or MN1: CXXC5 fusion genes, has the molecular phenotype and proliferation characteristics of MN1 fusion gene mutant ABM tumors, can still well simulate the characteristics of the ABM tumors when transplanted into animal brains, and can be used for preparing the astroblastoma cell model. Therefore, an important research tool is provided for mechanism research and drug development of ABM tumors.

The invention develops a double-line sequential targeted nano-drug delivery system, epigenetic regulation and traditional chemotherapy are combined, and the system is used for accurately and effectively treating acute myelogenous leukemia. The METTL3 inhibitor and the ROS-responsive daunorubicin prodrug are co-delivered in a single nano-drug, and the nano-preparation can realize continuous and double-path drug release according to the oxidation-reduction state in AML cells. In leukemia stem cells with low ROS level, STM2457 is released preferentially to induce differentiation and improve the ROS level of mitochondria, so that DA-ROS is activated, and the effect of delaying cytotoxicity is achieved. On the contrary, the AML mother cells with high ROS level can immediately trigger DA-ROS activation and release the two drugs at the same time, so that the tumor cells are directly killed. This ROS adaptive delivery strategy ensures spatial and temporal accuracy of drug release in heterogeneous AML cell populations.

Methods are provided for treating a subject for an EGFRvIII expressing glioblastoma. The methods of the present disclosure involve administering to the subject a molecular circuit that is primed by EGFRvIII to induce one or more encoded therapeutics specific for one or more antigens expressed by the glioblastoma. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions comprising gastrodin, wherein the gastrodin is produced by a genetically modified plant or plant cell, fungal cell, yeast cell, insect cell, or bacterial cell. In certain embodiments, the present disclosure provides methods and compositions for the production of gastrodin. In yet other embodiments, the present disclosure provides enhanced cells and methods for producing gastrodin.

The invention provides a mother battery piece, a battery piece, a preparation method of the mother battery piece and a photovoltaic module. The battery piece comprises a first semiconductor substrate; the first doped semiconductor layer is arranged in the central region; the isolation groove is formed in the first isolation area and surrounds the central area; wherein the side surface comprises a first sub-surface, and the first sub-surface is connected with the groove wall of the isolation groove; the tunneling passivation contact structure is at least arranged on the second surface; the first passivation layer at least covers the first doped semiconductor layer, the isolation groove and the first sub-surface; wherein the first sub-surface and the second surface are both provided with a plurality of square tower footing structures, the difference between the side length of the largest square tower footing structure on the first sub-surface and the side length of the largest square tower footing structure on the second surface is a first numerical value, and the first numerical value is smaller than or equal to 15 microns. The battery efficiency can be improved, and the manufacturing cost can be reduced.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

The present invention provides a GD2-targeting CAR-T cell and its preparation and application. Specifically, the present invention provides a GD2-targeting CAR construct, which comprises the scFv fragment of the humanized GD2 antibody 3F8, the human Fc fragment, the ICOS transmembrane region, the ICOS and 4-1BB intracellular regions (co-stimulatory signals), and CD3ζ. The present invention also provides a CAR-T cell based on the above CAR, its preparation method and application. The CAR-T cell of the present invention can significantly inhibit the proliferation of tumor cells in a subcutaneous model of neuroblastoma, has a significant in vivo anti-tumor effect, and can be used for the targeted treatment of neuroblastoma.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.

The invention discloses a physical induction method of poplar 2n pollen. The invention uses low temperature as an inducer to induce and treat poplar pollen mother cells to obtain poplar 2n pollen; further, by optimizing the technical conditions for inducing chromosome doubling of poplar pollen by low temperature treatment, the optimal technical parameters such as effective treatment period, treatment temperature and continuous treatment time are screened, and finally high-frequency poplar 2n pollen is obtained, and a technical system for low-temperature induction of poplar pollen chromosome doubling and breeding triploids is established, which greatly improves the ratio of poplar 2n pollen, and the male inflorescence of poplar treated by low temperature induction can shed pollen normally and has high pollen vitality, which is suitable for hybrid pollination of triploids; compared with the current colchicine induction and high temperature induction methods, the low temperature induction of 2n pollen has the advantages of simple operation, low cost, high relative safety, etc., and has theoretical and practical significance in constructing a new and efficient poplar triploid breeding technology system.

Disclosed herein are genetically engineered yeast cells capable of producing xylitol and characterized by a deletion or disruption in a native gene encoding an erythrose reductase at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to at least one of SEQ ID NO:295. The genetically engineered yeast cell may additionally be engineered to overexpress a native RPE enzyme, express an exogenous XPDH enzyme, express an exogenous XKS enzyme, express an exogenous XDH enzyme, overexpress a native X5PP enzyme, and / or express an exogenous X5PP enzyme.

The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.